Needham & Company Downgrades Spectranetics (SPNC) to Buy

Needham & Company downgraded Spectranetics (NASDAQ: SPNC) from Strong Buy to Buy with a price target of $27.00 on valuation.

Analyst Mike Matson commented, "We hosted SPNC's CEO, Scott Drake, and COO, Shar Matin, for investor meetings last week. Management was upbeat about Stellarex's ability to take share in the drug-coated balloon (DCB) market and SPNC's ability to sustain strong growth in the base Vascular Intervention business and we come away feeling more positive about the prospects for both. However, we downgrade SPNC to Buy from Strong Buy given its valuation."

For an analyst ratings summary and ratings history on Spectranetics click here. For more ratings news on Spectranetics click here.

Shares of Spectranetics closed at $24.01 yesterday.

You May Also Be Interested In

• Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'
• Prudential Financial (PRU) PT Raised to $116 at Evercore ISI
• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'